-
Product Insights
Plasma Cell Neoplasm – Drugs In Development, 2023
Global Markets Direct’s, ‘Plasma Cell Neoplasm - Drugs In Development, 2023’, provides an overview of the Plasma Cell Neoplasm pipeline landscape. The report provides comprehensive information on the therapeutics under development for Plasma Cell Neoplasm, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the...
-
Product Insights
Thyroid Cancer – Drugs In Development, 2023
Global Markets Direct’s, ‘Thyroid Cancer - Drugs In Development, 2023’, provides an overview of the Thyroid Cancer pipeline landscape. The report provides comprehensive information on the therapeutics under development for Thyroid Cancer, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Product Insights
Neuroblastoma – Drugs In Development, 2023
Global Markets Direct’s, ‘Neuroblastoma - Drugs In Development, 2023’, provides an overview of the Neuroblastoma pipeline landscape. The report provides comprehensive information on the therapeutics under development for Neuroblastoma, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key...
-
Product Insights
B-Cell Acute Lymphocytic Leukemia (B-Cell Acute Lymphoblastic Leukaemia) – Drugs In Development, 2023
Global Markets Direct’s, ‘B-Cell Acute Lymphocytic Leukemia (B-Cell Acute Lymphoblastic Leukaemia) - Drugs In Development, 2023’, provides an overview of the B-Cell Acute Lymphocytic Leukemia (B-Cell Acute Lymphoblastic Leukaemia) pipeline landscape. The report provides comprehensive information on the therapeutics under development for B-Cell Acute Lymphocytic Leukemia (B-Cell Acute Lymphoblastic Leukaemia), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the...
-
Product Insights
Neuroendocrine Cancer – Drugs In Development, 2023
Global Markets Direct’s, ‘Neuroendocrine Cancer - Drugs In Development, 2023’, provides an overview of the Neuroendocrine Cancer pipeline landscape. The report provides comprehensive information on the therapeutics under development for Neuroendocrine Cancer, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Product Insights
Marginal Zone B-cell Lymphoma – Drugs In Development, 2023
Global Markets Direct’s, ‘Marginal Zone B-cell Lymphoma - Drugs In Development, 2023’, provides an overview of the Marginal Zone B-cell Lymphoma pipeline landscape. The report provides comprehensive information on the therapeutics under development for Marginal Zone B-cell Lymphoma, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press...
-
Product Insights
Neuroendocrine Tumors – Drugs In Development, 2023
Global Markets Direct’s, ‘Neuroendocrine Tumors - Drugs In Development, 2023’, provides an overview of the Neuroendocrine Tumors pipeline landscape. The report provides comprehensive information on the therapeutics under development for Neuroendocrine Tumors, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Product Insights
Nodal Marginal Zone B-Cell Lymphoma – Drugs In Development, 2023
Global Markets Direct’s, ‘Nodal Marginal Zone B-Cell Lymphoma - Drugs In Development, 2023’, provides an overview of the Nodal Marginal Zone B-Cell Lymphoma pipeline landscape. The report provides comprehensive information on the therapeutics under development for Nodal Marginal Zone B-Cell Lymphoma, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – (Macitentan + Tadalafil) in Pulmonary Arterial Hypertension
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - (Macitentan + Tadalafil) in Pulmonary Arterial Hypertension report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. (Macitentan + Tadalafil) in Pulmonary Arterial Hypertension Drug Details:...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – BMS-986415 in Head And Neck Cancer Squamous Cell Carcinoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - BMS-986415 in Head And Neck Cancer Squamous Cell Carcinoma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. BMS-986415 in Head And Neck Cancer Squamous...